Skip to content

Vestibular Socket Therapy in Immediate Implants With Grafting Materials

A Comparative Study Evaluating Vestibular Socket Therapy in Immediate Implants Using Different Grafting Materials

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04957654
Enrollment
24
Registered
2021-07-12
Start date
2021-03-16
Completion date
2022-07-01
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Implant, Extarction Socket, Tooth Extraction

Brief summary

The current research aims at evaluating the outcomes of the vestibular socket therapy in immediate implants using collagen plug, demineralized freeze-dried bone allograft, and deproteinized bovine bone minerals at both radiographic and clinical levels

Interventions

OTHERVST with collagen plug soaked in blood

-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood

OTHERVST with Allograft Demineralized bone matrix Grafton

-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton

OTHERVST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles

-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles

Sponsors

Mohamed Mofreh Hamada Hamed
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

statistician will be blind

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients will be included if they have one or more hopeless teeth without signs of acute infection in the maxillary anterior region. * Remaining roots or non-restorable teeth with sufficient bone apically and palatably to allow proper implant positioning with sufficient primary stability. * Optimal compliance as evidenced by no missed treatment appointments and a positive attitude towards oral hygiene. * Medically free

Exclusion criteria

* Medically compromised patients and systemic conditions precluding implant and periodontal surgery. * Smokers, diabetics, pregnant or lactating women. * History of chemotherapy, radiotherapy in head and/or neck region. * Bisphosphonate therapy

Design outcomes

Primary

MeasureTime frameDescription
changes in facial plate heightat baseline, 6 and 12 monthsEach group will be subjected to: Cone beam computed tomography (CBCT) at baseline, 6 months, and 12months to assess height of labial (facial) plate of bone and implant survival
changes in facial plate thicknessat baseline, 6 and 12 monthsEach group will be subjected to: Cone beam computed tomography (CBCT) at baseline, 6 months, and 12months to assess the thickness of the labial (facial) plate of bone and implant survival

Secondary

MeasureTime frameDescription
changes in peri-implant mucosal levelat baseline, 3rd and 6th monthsEach group will be subjected to Intraoral scanning at baseline, 6 months and 12 months. The changes in peri-implant mucosal level will be assessed by superimposition of scanning files of different intervals to monitor the changes in surface area calculated by software.

Countries

Egypt

Contacts

Primary ContactMohamed M Hamed, BDS
mohamedhamed628@gmail.com01023888701

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026